Terence Flynn
Stock Analyst at Morgan Stanley
(3.93)
# 585
Out of 4,876 analysts
192
Total ratings
56.44%
Success rate
8.08%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Equal-Weight | $12 → $11 | $7.77 | +41.57% | 9 | May 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $24 → $22 | $8.39 | +162.22% | 6 | May 9, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $140 → $132 | $107.10 | +23.25% | 3 | May 6, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $15 → $10 | $9.89 | +1.11% | 10 | May 5, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $346 → $348 | $285.00 | +22.11% | 9 | May 1, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $241 → $250 | $185.92 | +34.47% | 16 | Apr 28, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $164 → $169 | $152.82 | +10.59% | 21 | Apr 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,146 → $1,124 | $783.84 | +43.40% | 19 | Apr 9, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $328 → $330 | $278.98 | +18.29% | 8 | Apr 9, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $14.28 | +341.33% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $47.21 | -32.22% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $106 | $78.71 | +34.67% | 16 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $11.79 | +44.19% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $9.78 | +12.47% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $46.46 | -16.06% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $24.27 | +27.73% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $21.33 | +453.21% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $3.12 | +1,053.85% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $35.69 | +42.90% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $128.21 | +31.04% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.49 | +438.72% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $126.43 | +244.85% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $321.18 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.34 | - | 1 | Jul 21, 2017 |
Arvinas
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $7.77
Upside: +41.57%
Arcus Biosciences
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $8.39
Upside: +162.22%
BioNTech SE
May 6, 2025
Maintains: Overweight
Price Target: $140 → $132
Current: $107.10
Upside: +23.25%
Organon & Co.
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.89
Upside: +1.11%
United Therapeutics
May 1, 2025
Maintains: Equal-Weight
Price Target: $346 → $348
Current: $285.00
Upside: +22.11%
AbbVie
Apr 28, 2025
Maintains: Overweight
Price Target: $241 → $250
Current: $185.92
Upside: +34.47%
Johnson & Johnson
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $164 → $169
Current: $152.82
Upside: +10.59%
Eli Lilly and Company
Apr 9, 2025
Maintains: Overweight
Price Target: $1,146 → $1,124
Current: $783.84
Upside: +43.40%
Amgen
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $278.98
Upside: +18.29%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $14.28
Upside: +341.33%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $47.21
Upside: -32.22%
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $78.71
Upside: +34.67%
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $11.79
Upside: +44.19%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $9.78
Upside: +12.47%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $46.46
Upside: -16.06%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $24.27
Upside: +27.73%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $21.33
Upside: +453.21%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $3.12
Upside: +1,053.85%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $35.69
Upside: +42.90%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $128.21
Upside: +31.04%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.49
Upside: +438.72%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $126.43
Upside: +244.85%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $321.18
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.34
Upside: -